Eglin c based drugs for treatment of disease
AssigneeThe Regents of the University of Michigan
InventorsTomoko Komiyama, Robert S. Fuller
Life of this patent
Estimating the term…
Abstract
The present invention relates to eglin c variants which inhibit proteases, and in particular to eglin c mutants at adventitious contact sites. The present invention also relates to eglin c variants which comprise mutations in both adventitious contact sites and at reactive loop sites. The present invention further relates to methods of preparing the eglin c variants, and methods of using the eglin c variants for treatment of diseases including acute bacterial, viral, and fungal infections.
Claims10
A composition comprising a protease inhibitor that is an eglin c variant, wherein the eglin c variant comprises SEQ ID NO.2 with the exception of an amino acid change at a position selected from the group consisting of Asp33, Tyr35, Leu37, Glu39, Gly40, Leu47, Tyr49, Asn50, His65 and His68.
A composition comprising a protease inhibitor that is an eglin c variant, wherein the eglin c variant comprises at least one at least one amino acid change at a position selected from the group consisting of Asp33, Tyr35, Leu37, Glu39, Gly40, Leu47, Tyr49, Asn50, His65 and His68 of SEQ ID NO:2, and further comprising at least one amino acid change at a position selected from the group consisting of Gly40, Ser41, Pro42, Val43, Thr44 and Arg45 of SEQ ID NO:2.
A composition comprising a protease inhibitor that is an eglin c variant, wherein the eglin c variant is selected from the group consisting of eglin c variants R4-, M4R1-, R4R1-, M4K1-, R4K1-, R6R4F1-, K2R1-, M4K2R1-, R4,K2R1-eglin, wherein the variant further comprises at least one amino acid chance at a position selected from the group consisting of Asp33, Tyr35, Leu37, Glu39, Gly40, Leu47, Tyr49, Asn50, His65 and His68 of SEQ ID NO:2.
Dependencies are inferred from the claim text.